ESTRO 37 Abstract book

S904

ESTRO 37

Results Of 3,473 patients treated 44% received a hypo- fractionated schedule. There was an increase in the use of hypofractionation in 2 states during this period. Uptake of hypofractionation varied by state (20--71%) and by radiation oncologist (3-100%). There was increasing use of hypofractionation with increasing age of the patient (61% for patients 70 years or older), lower tumour grade, ER positivity, but no difference by laterality or with increasing distance to treatment centre. Patients receiving chemotherapy were less likely to receive hypofractionation. On multivariate modelling increasing age, year of treatment, T stage, use of chemotherapy and Radiation Oncologist were all significant predictors of the use of hypofractionation (p<0.001). Conclusion Similar to other published experiences our data demonstrate variation in the uptake of hypofractionation for early stage breast cancer. Interestingly the overall rate of hypofractionation across this large private practice is very similar to the only other published Australian data. Radiation Oncologists(ROs) are more likely to use hypofractionation in older patients but there is variation between ROs and between states which is not explained by clinical factors. Our current plan is to explore whether rates of hypofractionation can be influenced by real time feedback to ROs using an in-house software development called RO Portal. This allows automatic download of structured data into Mosiaq and provision of patterns of practice dashboards to ROs. EP-1681 Loss of follow-up in cancer care for the management of cervix cancer patients J. PANDJATCHARAM 1 , P. Chinnakali 2 , V. Mohan 1 , N. Bharathnag 2 , K. Periasamy 1 , S.K. Soman 1 , K. Sri Harsha 1 1 JIPMER, Radiation Oncology, Puducherry, India 2 JIPMER, Preventive and Social Medicine, Puducherry, India

Among the 626 study participants, 372 (59.4%) had lost to follow-up at the time of the study at various stages of their management course since hospital registration. The distribution of patients who have lost to follow-up at various stages of the management is schematically depicted in the figure enclosed. The most common reason for loss to follow-up in our study was death while awaiting radiation treatment (33%) followed by long waiting period for radiotherapy (13%) while 5% could not continue their visits due to lack of chaperone support. Worsening clinical condition, long travel and feeling healthy were some minor reasons quoted. Around 2% had discontinued treatment and follow-up due to treatment related toxicities. Among 372 patients who had lost to follow-up, a sizeable number of patients (38%) could not be contacted over phone because of missing contact information. Patients who were planned for concurrent radiotherapy and chemotherapy were found to have significantly lesser risk in defaulting hopital visits than those who were planned for palliative treatments(<0.001). Age and stage of the disease were not found to be associated with loss to follow-up.

Purpose or Objective 1.

To determine the proportion lost to follow up (LFU) among uterine cervix cancer patients at three stages of their disease managment namely before initiation of radiotherapy, between radiotherapy and evaluation for response and subsequent follow up till 4 months. To document the reasons for Loss to Follow-Up at each stage since the day of registration in the hospital.

Conclusion Our study reveals that majority of cervical cancer patients registered in our regional cancer centre have been lost to follow up even before starting radiation treatment. So relevant measures to reduce the waiting period like increasing cancer treatment facilities and better geographic distribution of such centres to avoid added burden to tertiary cancer hospitals may help in reducing the loss to follow-up. EP-1682 A single institution cross-sectional audit of outcomes in patients with brain metastases M. O'Cathail 1 , J. Weller 2 , J. Ho 1 , R. Clements 1 , J. Christian 1 , V. Crosby 2 , L. Aznar-Garcia 1 1 Notthingham University Hospitals NHS Trust, Oncology and Radiotherapy, Notthingham, United Kingdom 2 Notthingham University Hospitals NHS Trust, Palliative care, Notthingham, United Kingdom Purpose or Objective Up to 30% of patients with metastatic disease will develop brain metastases (BM). Patients are living longer due to advances in systemic anti-cancer therapy, however these are often ineffective at controlling BM. There is no consensus on management. Options include surgery, stereotactic radiosurgery (SRS), whole brain radiotherapy (WBRT) & steroids. In our region, the

2.

Material and Methods The departmental records of uterine cervical cancer patients who were registered in the Radiation Oncology out-patient department of our regional cancer centre between January 2016 and December 2016 were collected for this study. Data about socio-demographic variables, disease and treatment-related information were retrieved from the records. Patients who missed their due follow-up visit at each stage of their course of management were identified from the departmental follow-up register and contacted through phone for patients’ vital status and for determining the reasons for loss to follow-up Results The mean age was 53 ± 10 years. Thirty six percent of patients had Stage III & 23% had Stage II disease. Sixty four percent had been planned for radical radiation, 5% for adjuvant radiotherapy and 4% for palliative radiation.